Prediction of Impending Type 1 Diabetes Through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
Overview
Authors
Affiliations
Background: The hyperglycemic clamp test, the gold standard of beta cell function, predicts impending type 1 diabetes in islet autoantibody-positive individuals, but the latter may benefit from less invasive function tests such as the proinsulin:C-peptide ratio (PI:C). The present study aims to optimize precision of PI:C measurements by automating a dual-label trefoil-type time-resolved fluorescence immunoassay (TT-TRFIA), and to compare its diagnostic performance for predicting type 1 diabetes with that of clamp-derived C-peptide release.
Methods: Between-day imprecision (n = 20) and split-sample analysis (n = 95) were used to compare TT-TRFIA (AutoDelfia, Perkin-Elmer) with separate methods for proinsulin (in-house TRFIA) and C-peptide (Elecsys, Roche). High-risk multiple autoantibody-positive first-degree relatives (n = 49; age 5-39) were tested for fasting PI:C, HOMA2-IR and hyperglycemic clamp and followed for 20-57 months (interquartile range).
Results: TT-TRFIA values for proinsulin, C-peptide and PI:C correlated significantly (r2 = 0.96-0.99; P<0.001) with results obtained with separate methods. TT-TRFIA achieved better between-day %CV for PI:C at three different levels (4.5-7.1 vs 6.7-9.5 for separate methods). In high-risk relatives fasting PI:C was significantly and inversely correlated (rs = -0.596; P<0.001) with first-phase C-peptide release during clamp (also with second phase release, only available for age 12-39 years; n = 31), but only after normalization for HOMA2-IR. In ROC- and Cox regression analysis, HOMA2-IR-corrected PI:C predicted 2-year progression to diabetes equally well as clamp-derived C-peptide release.
Conclusions: The reproducibility of PI:C benefits from the automated simultaneous determination of both hormones. HOMA2-IR-corrected PI:C may serve as a minimally invasive alternative to the more tedious hyperglycemic clamp test.
Apaolaza P, Chen Y, Grewal K, Lurz Y, Boulassel S, Verchere C Diabetologia. 2024; 67(12):2771-2785.
PMID: 39404844 PMC: 11604696. DOI: 10.1007/s00125-024-06275-5.
Sims E, Geyer S, Long S, Herold K Diabetologia. 2023; 66(12):2283-2291.
PMID: 37667106 PMC: 10914155. DOI: 10.1007/s00125-023-06003-5.
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.
Kahn S, Chen Y, Esser N, Taylor A, van Raalte D, Zraika S Endocr Rev. 2021; 42(5):528-583.
PMID: 34180979 PMC: 9115372. DOI: 10.1210/endrev/bnab021.
Altered β-Cell Prohormone Processing and Secretion in Type 1 Diabetes.
Rodriguez-Calvo T, Chen Y, Verchere C, Haataja L, Arvan P, Leete P Diabetes. 2021; 70(5):1038-1050.
PMID: 33947721 PMC: 8173804. DOI: 10.2337/dbi20-0034.
The role of beta-cell dysfunction in early type 1 diabetes.
Sims E, Mirmira R, Evans-Molina C Curr Opin Endocrinol Diabetes Obes. 2020; 27(4):215-224.
PMID: 32618633 PMC: 7365587. DOI: 10.1097/MED.0000000000000548.